Cephalon/Chiron Myotrophin (IGF-1) shows 25% reduction in rate of ALS progression, company reports.
Executive Summary
CEPHALON/CHIRON MYOTROPHIN 8-POINT ALS SCORE DIFFERENCE FROM PLACEBO after nine months of therapy is significant in a Phase III study, Cephalon Senior-VP Michael Murphy, MD/PhD, reported June 10 at the World Federation of Neurology Committee on Motor Neuron Diseases in Talloires, France. Amyotrophic lateral sclerosis patients receiving the highest dose of Myotrophin (somatomedin-C) had an average 18-point increase from baseline on the Appel ALS scale compared to a 26-point increase for placebo-treated patients. A 20-point change indicates a major functional change in the ability of Lou Gehrig's disease patients to care for themselves.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth